Anixa Biosciences, Inc. (ANIX) News
Filter ANIX News Items
ANIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ANIX News From Around the Web
Below are the latest news stories about ANIXA BIOSCIENCES INC that investors may wish to consider to help them evaluate ANIX as an investment opportunity.
iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024RALEIGH, NC / ACCESSWIRE / December 6, 2024 / iAccess Alpha's "Buyside Best Ideas Virtual Winter Conference" is taking place on December 10-11, 2024. The conference begins on Tuesday, December 10, with Company presentations beginning at 10:00 a.m. ... |
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced today that it will be participating in the iAccess Alpha Virtual Best Ideas Winter Conference 2024 being held on December 10th and 11th, 2024. |
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Could Be 20% Below Their Intrinsic Value EstimateKey Insights Anixa Biosciences' estimated fair value is US$4.15 based on 2 Stage Free Cash Flow to Equity Current share... |
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical TrialAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). |
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of D |
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, will be made publicly available on the Company's website at 12:15pm CT on November 8, 2024. Concurrently, the Company will issue a press release providing an analysis of |
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its presentation at the Sidoti Micro-Cap Virtual Conference, taking place November 13-14, 2024. Anixa Chairman and CEO Dr. Amit Kumar will present an overview of the Company and its clinical programs. |
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas, from November 6-10, 2024. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. |
US Penny Stocks To Consider In October 2024As the U.S. stock market stabilizes after a recent sell-off, with major indices like the S&P 500 and Nasdaq showing signs of recovery, investors are keenly observing earnings reports and economic indicators for clues about future trends. In this context, penny stocks—often associated with smaller or newer companies—remain an intriguing option for those willing to explore beyond established names. Despite their name suggesting a bygone era, these stocks continue to offer potential value... |
Anixa Biosciences administers second CAR-T dose in ovarian cancer trialThe ongoing Phase I clinical trial is being conducted in partnership with Moffitt Cancer Centre. |